RNS Number : 4596I
Shield Therapeutics PLC
14 December 2020

**Shield Therapeutics plc**
("Shield" or the "Group" or the "Company")

**Investor Presentation**

**London, UK, 14 December 2020:** Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), announces that it will provide a live presentation presented by CEO, Tim Watts, on Wednesday 16 December at 4.30pm.

The presentation will be hosted through the digital platform Investor Meet Company. Investors can sign up to Investor Meet Company for free and add to meet Shield Therapeutics plc via the following link:
https://www.investormeetcompany.com/shield-therapeutics-plc/register-investor

Questions can be submitted pre-event via your IMC dashboard or in real time during the presentation, via the "Ask a Question" function. Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards. No new price sensitive information will be disclosed, and a PDF of the presentation will be uploaded to the Company's website.

**For further information please contact:**

**Shield Therapeutics plc** www.shieldtherapeutics.com
Tim Watts, CEO +44 (0)20 7186 8500

***Nominated Adviser and Joint Broker***
**Peel Hunt LLP**
James Steel/Dr Christopher Golden +44 (0)20 7418 8900

***Joint Broker***
**finnCap Ltd** +44 (0)20 7220 0500
Geoff Nash/Matt Radley/Alice Lane

***Financial PR & IR Advisor***
**Walbrook PR** +44 (0)20 7933 8780 or shield@walbrookpr.com
Paul McManus/Lianne Cawthorne +44 (0)7980 541 893 / +44 (0)7584 391 303

**About Shield Therapeutics plc**

Shield is a de-risked, specialty pharmaceutical company focused on commercialising its lead product, Feraccru®/Accrufer®, a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Feraccru®/Accrufer® has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. Feraccru® is commercialised in the UK and Europe by Norgine B.V. and the Company is currently in the process of selecting a commercialisation partner for the US market. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan.

For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCUASKRRVUUAAA